Aveo shares surge on a European licensing pact

Shares of Aveo Oncology ($AVEO) shot up 27% this morning after the biotech announced a European licensing pact for its long-troubled cancer drug tivozanib. The deal starts small but could end big, with Aveo getting a $2.5 million upfront and a commitment of up to $394 million in milestones from EUSA Pharma. EUSA plans to file an application in Europe in early 2016 for use against advanced renal cell carcinoma. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.